Agilent Technologies Inc. announced the release of a new automated parallel capillary electrophoresis system for protein analysis – the Agilent ...
Pfizer does not endorse TRC Capital Investment’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in respons...
Unlocking the next generation of life sciences innovations will depend on researchers' abilities to not just uncover new data, but to identify patterns at ...
Base4 Biotechnology (formerly known as Nymirum) announced that it has expanded its license agreement with Servier to strengthen the companies' strategic co...
“It’s an honor to be named in the Dow Jones Sustainability Indices for a ninth consecutive year. I am particularly proud of our team’s pr...
Omniose, a preclinical stage biotechnology company, today announced an exclusive collaboration agreement with AstraZeneca for the search for potential vacc...
- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust imm...
QIAGEN announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase tha...
QIAGEN announced a strategic plan to step up investments over the next five years in its market-leading QIAGEN Digital Insights (QDI) business. These inve...
QIAGEN to open regional headquarters in Riyadh, Saudi Arabia, at the beginning of 2024 to support growing presence in the region QIAGEN signed Memor...
CG Life’s fresh new look and feel embodies how everything the agency does with its client partners is shaped by the profound impact of science on eve...
Inaugural strategy is one of the largest ever first-time private life sciences growth funds Fundraise closed above its original target, reflecting stron...
Tome Biosciences, Inc., the programmable genomic integration (PGI) company, announces that it has acquired Replace Therapeutics Inc., a private biote...
SNK01 consists of a non-genetically modified NK cell product with enhanced cytotoxicity and activating receptor expression for the treatment of moderate AD...
© 2024 Biopharma Boardroom. All Rights Reserved.
